BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.44 CNY | -2.10% |
|
+14.36% | +1.26% |
| May. 07 | China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7% | MT |
| May. 07 | BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3% | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 1.05B 146M | Sales 2022 | 1.02B 141M | Capitalization | 9.54B 1.32B |
|---|---|---|---|---|---|
| Net income 2021 | 244M 33.77M | Net income 2022 | 240M 33.22M | EV / Sales 2021 | 14.8 x |
| Net Debt 2021 | 565M 78.17M | Net Debt 2022 | 791M 109M | EV / Sales 2022 | 10.2 x |
| P/E ratio 2021 |
61.2
x | P/E ratio 2022 |
38.9
x | Employees | 1,128 |
| Yield 2021 |
0.33% | Yield 2022 |
0.51% | Free-Float | 48.25% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.10% | ||
| 1 week | +14.36% | ||
| Current month | +14.36% | ||
| 1 month | +22.88% | ||
| 3 months | +43.71% | ||
| 6 months | +4.76% | ||
| Current year | +1.26% |
1 week
31.08
36.66
1 month
24.4336.66
Current year
19.6336.66
1 year
17.8146.88
3 years
17.1048.49
5 years
17.1072.43
10 years
17.1072.43
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Dong Yuan
CEO | Chief Executive Officer | 54 | 01-10-25 |
Yuan Lai Zou
DFI | Director of Finance/CFO | 53 | 10-12-31 |
Fan Hang
BRD | Director/Board Member | 38 | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jian Dong Yuan
CEO | Chief Executive Officer | 54 | 01-10-25 |
Kai Li
PRN | Corporate Officer/Principal | 48 | 06-12-31 |
Ying Xian Shen
BRD | Director/Board Member | 38 | 17-09-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.72% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 35.44 | -2.10% | 10 900 040 |
| 24-05-09 | 36.2 | +5.14% | 12,767,060 |
| 24-05-08 | 34.43 | -3.01% | 15,460,090 |
| 24-05-07 | 35.5 | +7.25% | 22,979,760 |
| 24-05-06 | 33.1 | +6.81% | 14,356,360 |
End-of-day quote Shanghai S.E., May 09, 2024
More quotes
BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research, development and production of generic drugs and original new drugs. The Company's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The Company's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The Company mainly conducts its businesses in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.26% | 2.12B | |
| +31.17% | 695B | |
| +26.51% | 568B | |
| -4.59% | 361B | |
| +19.52% | 330B | |
| +3.79% | 283B | |
| +16.70% | 239B | |
| +8.78% | 204B | |
| -7.93% | 198B | |
| +9.04% | 168B |
- Stock Market
- Equities
- 688166 Stock